Cell based assay with Human VEGF165 Protein 4887

Human VEGF165 Protein 4887

$285.00 – $950.00

Summary

Expression: HEK293
Active: Yes (cell based assay)
Amino Acid Range: Ala27-Arg191

SKU: 4887parent Categories: proteins, Recombinant proteins Tag: active proteins

Weight	1 lbs
Dimensions	9 × 5 × 2 in
accession	P15692
express system	HEK293
product tag	No Tag
purity	> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC
background	Human papillomavirus (HPV) infection is an established risk factor for cervical carcinogenesis. VEGF165 was significantly higher, whereas VEGFC and VEGFD were significantly lower in malignant cervical carcinoma tissues as compared to normal cervix tissues. Expression levels of VEGF121 and VEGFC were significantly associated with type of tumor growth while VEGF165 was significantly associated with lymph node metastasis.
molecular weight	The protein has a predicted MW of 19.2 kDa. Due to glycosylation, the protein migrates to 20-30 kDa based on Tris-Bis PAGE result.
available size	100 µg, 500 µg
endotoxin	Less than 0.05EU per μg by the LAL method.

Human VEGF165 Protein 4887

protein

Size and concentration 100, 500µg and lyophilized
Form Lyophilized
Storage Instructions Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Storage buffer Shipped at ambient temperature.
Purity > 95% as determined by Tris-Bis PAGE

target relevance
Human papillomavirus (HPV) infection is an established risk factor for cervical carcinogenesis. VEGF165 was significantly higher, whereas VEGFC and VEGFD were significantly lower in malignant cervical carcinoma tissues as compared to normal cervix tissues. Expression levels of VEGF121 and VEGFC were significantly associated with type of tumor growth while VEGF165 was significantly associated with lymph node metastasis.
Protein names Vascular endothelial growth factor A, long form (L-VEGF) (Vascular permeability factor) (VPF) [Cleaved into: N-VEGF; VEGFA]
Gene names VEGFA,VEGFA VEGF
Protein family PDGF/VEGF growth factor family
Mass 9606Da
Function [N-VEGF]: Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia-mediated cell death (By similarity).; [VEGFA]: Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth (PubMed:34530889). Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Binds to the NRP1/neuropilin-1 receptor. Binding to NRP1 initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). Also binds the DEAR/FBXW7-AS1 receptor (PubMed:17446437).; [Isoform VEGF165B]: Binds to the KDR receptor but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
Subellular location [N-VEGF]: Cytoplasm. Nucleus. Note=Cytoplasmic in normoxic conditions and localizes to the nucleus under hypoxic conditions.; [VEGFA]: Secreted .; [Isoform L-VEGF189]: Endoplasmic reticulum. Golgi apparatus. Secreted, extracellular space, extracellular matrix .; [Isoform VEGF121]: Secreted .; [Isoform VEGF165]: Secreted .; [Isoform VEGF189]: Secreted. Note=Cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
Tissues Higher expression in pituitary tumors than the pituitary gland.; [Isoform VEGF189]: Widely expressed.; [Isoform VEGF165]: Widely expressed.; [Isoform VEGF121]: Widely expressed.; [Isoform VEGF206]: Not widely expressed.; [Isoform VEGF145]: Not widely expressed.
Structure [VEGFA]: Homodimer; disulfide-linked (By similarity). Also found as heterodimer with PGF (By similarity). Interacts with NRP1 (PubMed:26503042). Interacts with isoform 2 of BSG (PubMed:25825981). Interacts with CD82; this interaction inhibits VEGFA-mediated signaling pathway (PubMed:34530889).
Post-translational modification [Vascular endothelial growth factor A, long form]: Produced by use of an alternative upstream CUG codon and post-translationally processed into the N-terminal N-VEGF form and the C-terminal secreted VEGFA form.
Target Relevance information above includes information from UniProt accession: P15692
The UniProt Consortium

Data

Immobilized Human VEGF165 at 1µg/ml (100µl/Well) on the plate. Dose response curve for Biotinylated Human VEGFR1, His Tag with the EC50 of 46.4ng/ml determined by ELISA (QC Test).

Immobilized Human VEGF165 at 1µg/ml (100µl/Well) on the plate. Dose response curve for Human VEGFR2, mFc Tag with the EC50 of 42.3ng/ml determined by ELISA.

Cell based assay with Human VEGF165 Protein

Human VEGF165 stimulates proliferation of human umbilical vein endothelial cells (HUVEC) with the ED50 for this effect is 2.57ng/mL (QC Test).

The purity of Human VEGF165 is greater than 95% as determined by SEC-HPLC.

Human VEGF165 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

Publications

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.